Integration of bioanalytical measurements using PK-PD modeling and simulation: Implications for antibody-drug conjugate development

Bioanalysis

Volumn 7, Issue 13, 2015, Pages 1633-1648

  Khot, Antari ^a   Sharma, Sharad ^a   Shah, Dhaval K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE;

AREA UNDER THE CURVE; BREAST CANCER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STABILITY; DRUG TUMOR LEVEL; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PLASMA CLEARANCE; PROGRESSION FREE SURVIVAL; REVIEW; SIMULATION; SURVIVAL PREDICTION; THROMBOCYTOPENIA; TOXICOKINETICS; TUMOR VOLUME; BIOASSAY; DRUG DESIGN; IMMUNOLOGY; PHARMACOKINETICS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; PHARMACOKINETICS;

EID: 84938372190     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.85     Document Type: Review

References (31)

1. Gorovits B, Alley SC, Bilic S et al. Bioanalysis of antibody- drug conjugates: American Association of Pharmaceutical Scientists Antibody-drug Conjugate Working Group position paper. Bioanalysis 5(9), 997-1006 (2013
2. Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab. Dispos. 42(11), 1914-1920 (2014
3. Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm. Res. (2015) (Epub ahead of print
4. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012
5. Jackson D, Atkinson J, Guevara CI et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE 9(1), e83865 (2014
6. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody- drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 16(5), 994-1008 (2014
7. Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16(3), 888-897 (2010
8. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J. Pharmacokinet. Pharmacodyn. 39(6), 643-659 (2012
9. Shah DK, King LE, Han X et al. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J. 16(3), 452-463 (2014
10. Lu D, Joshi A, Wang B et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2- positive metastatic breast cancer. Clin. Pharmacokinet. 52(8), 657-672 (2013
11. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J. Pharmacokinet. Pharmacodyn. 41(1), 35-47 (2014
12. Lu D, Jin JY, Girish S et al. Semi-mechanistic multipleanalyte pharmacokinetic model for an antibody-drugconjugate in cynomolgus monkeys. Pharm. Res. 32(6), 1907-1919 (2014
13. Chudasama VL, Schaedeli Stark F, Harrold JM et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 92(4), 520-527 (2012
14. Sukumaran S, Gadkar K, Zhang C et al. Mechanism-based pharmacokinetic/pharmacodynamic model for THIOMAB drug conjugates. Pharm. Res. 32(6), 1884-1893 (2014
15. Alley SC, Zhang X, Okeley NM et al. The pharmacologic basis for antibody-auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330(3), 932-938 (2009
16. Erickson HK, Lewis Phillips GD, Leipold DD et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther. 11(5), 1133-1142 (2012
17. Wada R, Erickson HK, Lewis Phillips GD et al. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother. Pharmacol. 74(5), 969-980 (2014
18. Shah DK, Barletta F, Betts A, Hansel S. Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers perspective. Bioanalysis 5(9), 989-992 (2013
19. Shah DK, Balthasar JP. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J. Pharmacokinet. Pharmacodyn. 41(1), 55-69 (2014
20. Shah DK, Balthasar JP. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecaninduced toxicity in mice. Int. J. Pharm. 465(1-2), 228-238 (2014
21. Chen Y, Samineni D, Mukadam S et al. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. Clin. Pharmacokinet. 54(1), 81-93 (2015
22. Zhao B, Zheng S, Alley SC. Physiologically-based pharmacokinetic modeling of an anti-cd70 auristatin antibody-drug conjugate in tumor-bearing mice. Presented at: American Conference on Pharmacometrics 2011. San Diego, CA, 3-6 April 2011.
23. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacokinet. Pharmacodyn. 39(1), 67-86 (2012
24. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn. 34(5), 687-709 (2007
25. Jumbe NL, Xin Y, Leipold DD et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J. Pharmacokinet. Pharmacodyn. 37(3), 221-242 (2010
26. Haddish-Berhane N, Shah DK, Ma D et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J. Pharmacokinet. Pharmacodyn. 40(5), 557-571 (2013
27. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20(24), 4713-4721 (2002
28. Tatipalli M, Derendorf H. Semi-physiological population PK/PD model of ADC neutropenia. Pharm. Sci. [Masters]. University Of Florida, USA (2012
29. Mugundu G, Vandendries E, Boni J. Use of pharmacokineticpharmacodynamic modeling to characterize platelet response following inotuzumab ozogamicin treatment in patients with follicular or diffuse large B-cell non-Hodgkins lymphoma Presented at: AACR 103rd Annual Meeting 2012. Chicago, USA, 31 March - 4 April 2012.
30. Bender BC, Schaedeli-Stark F, Koch R et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother. Pharmacol. 70(4), 591-601 (2012
31. Firer MA. Antibody-drug conjugates in cancer therapy - filling in the potholes that lie ahead. OA Cancer 1(1) (2013).